Van Hulzen Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-4,600
| Closed | -$607K | – | 342 |
|
|
2025
Q1 | $607K | Sell |
4,600
-400
| -8% | -$49.8K | 0.06% | 192 |
|
|
2024
Q4 | $418K | Hold |
5,000
| – | – | 0.03% | 236 |
|
|
2024
Q3 | $366K | Sell |
5,000
-300
| -6% | -$22.5K | 0.03% | 243 |
|
|
2024
Q2 | $363K | Hold |
5,300
| – | – | 0.02% | 230 |
|
|
2024
Q1 | $367K | Sell |
5,300
-400
| -7% | -$27.5K | 0.02% | 246 |
|
|
2023
Q4 | $408K | Sell |
5,700
-300
| -5% | -$17.3K | 0.03% | 236 |
|
|
2023
Q3 | $313K | Hold |
6,000
| – | – | 0.02% | 244 |
|
|
2023
Q2 | $380K | Sell |
6,000
-400
| -6% | -$24.9K | 0.03% | 213 |
|
|
2023
Q1 | $347K | Hold |
6,400
| – | – | 0.03% | 214 |
|
|
2022
Q4 | $339K | Hold |
6,400
| – | – | 0.04% | 214 |
|
|
2022
Q3 | $298K | Hold |
6,400
| – | – | 0.04% | 214 |
|
|
2022
Q2 | $365K | Sell |
6,400
-200
| -3% | -$11.3K | 0.04% | 197 |
|
|
2022
Q1 | $404K | Sell |
6,600
-500
| -7% | -$26K | 0.04% | 197 |
|
|
2021
Q4 | $372K | Hold |
7,100
| – | – | 0.04% | 210 |
|
|
2021
Q3 | $265K | Sell |
7,100
-1,900
| -21% | -$66.1K | 0.04% | 223 |
|
|
2021
Q2 | $367K | Sell |
9,000
-800
| -8% | -$29.6K | 0.06% | 182 |
|
|
2021
Q1 | $333K | Sell |
9,800
-1,200
| -11% | -$41.6K | 0.05% | 187 |
|
|
2020
Q4 | $350K | Buy |
11,000
+200
| +2% | +$5.26K | 0.05% | 189 |
|
|
2020
Q3 | $277K | Buy |
10,800
+200
| +2% | +$4.56K | 0.04% | 204 |
|
|
2020
Q2 | $272K | Buy |
+10,600
| New | +$215K | 0.04% | 201 |
|
Other funds holding ITCI
Van Hulzen Asset Management's ITCI Position: Q2 2025 in Review
Van Hulzen Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 4,600 shares — an estimated $607K sold.
Van Hulzen Asset Management first reported a position in ITCI in Q2 2020 and held it in 20 quarters. The position peaked at $607K in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Van Hulzen Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Van Hulzen Asset Management sold 4,600 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $607K.
- Van Hulzen Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2020 and held it in 20 quarters.
- Van Hulzen Asset Management's Intra-Cellular Therapies Inc. position peaked at $607K in Q1 2025.
- 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Van Hulzen Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.